Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma

Authors: Jian Wang, Jingwu Li, Junling Shen, Chen Wang, Lili Yang, Xinwei Zhang

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

miR-182 is one of the most significantly up-regulated miRNAs in hepatocellular carcinoma (HCC). Metastasis suppressor 1 (MTSS1), one target gene of miR-182, plays an important role in the metastasis of cancers. However, it remains unclear what role does function and mechanism of miR-182 and MTSS1play in HCC.

Methods

miR-182 expression was tested in 86 cases of paired HCC and normal tissues by real-time PCR and the relationships between miR-182 expression and clinicopathological parameters were analyzed. The expression of MTSS1 was evaluated by immunohistochemistry and western blot in the above tissues and its correlation with miR-182 expression was analyzed. Moreover, western blot and invasion assays were performed after transfection of pre-miR-182 or anti-miR-182 to HCC cell lines. In addition, luciferase assays was performed to confirm the regulation of miR-182 on MTSS1.

Results

Compared with normal tissue, miR-182 was up-regulated and MTSS1 was down-regulated in HCC tissues. Moreover, the over-expression of miR-182 was correlated with intrahepatic metastasis (p = 0.034) and poor prognosis (p = 0.039) of HCC patients. There was a negative correlation between miR-182 and MTSS1 expression in both HCC tissues (r = −0.673, p < 0.01) and HCC cell lines (r = −0.931, p = 0.021). Furthermore, the up-regulation of miR-182 resulted in the down-regulation of MTSS1 and increased invasive potential of HUH-1, and reverse results were also confirmed when the expression of miR-182 was inhibited. In addition, the results of the luciferase assay demonstrated the targeted regulation of miR-182 on MTSS1.

Conclusions

miR-182 could promote metastasis of HCC and inhibit the expression of MTSS1. miR-182 and MTSS1 are potential prognostic markers and/or therapeutic targets in HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schütte K, Bornschein J, Malfertheiner P: Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis. 2009, 27: 80-92.PubMed Schütte K, Bornschein J, Malfertheiner P: Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis. 2009, 27: 80-92.PubMed
2.
go back to reference Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, Li H, Hao X: Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg. 2008, 12: 1540-1547. 10.1007/s11605-008-0591-y.CrossRefPubMed Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, Li H, Hao X: Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg. 2008, 12: 1540-1547. 10.1007/s11605-008-0591-y.CrossRefPubMed
3.
go back to reference Fan HL, Chen TW, Hsieh CB, Jan HC, His SC, De-Chuan C, Chu CH, Yu JC: Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria. Am J Surg. 2010, 200: 252-257. 10.1016/j.amjsurg.2009.07.049.CrossRefPubMed Fan HL, Chen TW, Hsieh CB, Jan HC, His SC, De-Chuan C, Chu CH, Yu JC: Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria. Am J Surg. 2010, 200: 252-257. 10.1016/j.amjsurg.2009.07.049.CrossRefPubMed
4.
go back to reference Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M: Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007, 141: 196-202. 10.1016/j.surg.2006.06.033.CrossRefPubMed Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M: Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007, 141: 196-202. 10.1016/j.surg.2006.06.033.CrossRefPubMed
5.
go back to reference Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA: MicroRNAs–the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009, 9: 293-302. 10.1038/nrc2619.CrossRefPubMed Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA: MicroRNAs–the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009, 9: 293-302. 10.1038/nrc2619.CrossRefPubMed
7.
go back to reference Trujillo RD, Yue SB, Tang Y, O'Gorman WE, Chen CZ: The potential functions of primary microRNAs in target recognition and repression. EMBO J. 2010, 29: 3272-3285. 10.1038/emboj.2010.208.CrossRefPubMedPubMedCentral Trujillo RD, Yue SB, Tang Y, O'Gorman WE, Chen CZ: The potential functions of primary microRNAs in target recognition and repression. EMBO J. 2010, 29: 3272-3285. 10.1038/emboj.2010.208.CrossRefPubMedPubMedCentral
8.
go back to reference Garzon R, Calin GA, Croce CM: MicroRNAs in Cancer. Annu Rev Med. 2009, 60: 167-179. 10.1146/annurev.med.59.053006.104707.CrossRefPubMed Garzon R, Calin GA, Croce CM: MicroRNAs in Cancer. Annu Rev Med. 2009, 60: 167-179. 10.1146/annurev.med.59.053006.104707.CrossRefPubMed
9.
go back to reference Law PT, Wong N: Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011, 26: 437-449. 10.1111/j.1440-1746.2010.06512.x.CrossRefPubMed Law PT, Wong N: Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011, 26: 437-449. 10.1111/j.1440-1746.2010.06512.x.CrossRefPubMed
10.
go back to reference Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, McCready D, Fyles A, Liu FF: MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 2011, 71: 2926-2937. 10.1158/0008-5472.CAN-10-3369.CrossRefPubMed Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, McCready D, Fyles A, Liu FF: MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 2011, 71: 2926-2937. 10.1158/0008-5472.CAN-10-3369.CrossRefPubMed
11.
go back to reference Patnaik SK, Kannisto E, Knudsen S, Yendamuri S: Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 2010, 70: 36-45. 10.1158/0008-5472.CAN-09-3153.CrossRefPubMed Patnaik SK, Kannisto E, Knudsen S, Yendamuri S: Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 2010, 70: 36-45. 10.1158/0008-5472.CAN-09-3153.CrossRefPubMed
12.
go back to reference Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H, Bremnes RM, Busund LT: Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer. 2011, 117: 3193-3200. 10.1002/cncr.25907.CrossRefPubMed Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H, Bremnes RM, Busund LT: Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer. 2011, 117: 3193-3200. 10.1002/cncr.25907.CrossRefPubMed
13.
go back to reference Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E: AberrantmiR-182expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA. 2009, 106: 1814-1819. 10.1073/pnas.0808263106.CrossRefPubMedPubMedCentral Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E: AberrantmiR-182expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA. 2009, 106: 1814-1819. 10.1073/pnas.0808263106.CrossRefPubMedPubMedCentral
14.
go back to reference Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA: microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010, 116: 945-952. 10.1182/blood-2010-01-263889.CrossRefPubMed Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA: microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010, 116: 945-952. 10.1182/blood-2010-01-263889.CrossRefPubMed
15.
go back to reference Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P, Lee CG: Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem. 2008, 283: 13205-13215. 10.1074/jbc.M707629200.CrossRefPubMed Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P, Lee CG: Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem. 2008, 283: 13205-13215. 10.1074/jbc.M707629200.CrossRefPubMed
16.
go back to reference Parr C, Jiang WG: Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer. 2009, 45: 1673-1683. 10.1016/j.ejca.2009.02.019.CrossRefPubMed Parr C, Jiang WG: Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer. 2009, 45: 1673-1683. 10.1016/j.ejca.2009.02.019.CrossRefPubMed
17.
go back to reference Liu K, Wang G, Ding H, Chen Y, Yu G, Wang J: Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer. 2010, 10: 428-10.1186/1471-2407-10-428.CrossRefPubMedPubMedCentral Liu K, Wang G, Ding H, Chen Y, Yu G, Wang J: Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer. 2010, 10: 428-10.1186/1471-2407-10-428.CrossRefPubMedPubMedCentral
18.
go back to reference Lee YG, Macoska JA, Korenchuk S, Pienta KJ: MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia. 2002, 4: 291-294. 10.1038/sj.neo.7900231.CrossRefPubMedPubMedCentral Lee YG, Macoska JA, Korenchuk S, Pienta KJ: MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia. 2002, 4: 291-294. 10.1038/sj.neo.7900231.CrossRefPubMedPubMedCentral
19.
go back to reference Nixdorf S, Grimm MO, Loberg R, Marreiros A, Russell PJ, Pienta KJ, Jackson P: Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Lett. 2004, 215: 209-220. 10.1016/j.canlet.2004.05.002.CrossRefPubMed Nixdorf S, Grimm MO, Loberg R, Marreiros A, Russell PJ, Pienta KJ, Jackson P: Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Lett. 2004, 215: 209-220. 10.1016/j.canlet.2004.05.002.CrossRefPubMed
20.
go back to reference Lin J, Liu J, Wang Y, Zhu J, Zhou K, Smith N, Zhan X: Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein. Oncogene. 2005, 24: 2059-2066. 10.1038/sj.onc.1208412.CrossRefPubMed Lin J, Liu J, Wang Y, Zhu J, Zhou K, Smith N, Zhan X: Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein. Oncogene. 2005, 24: 2059-2066. 10.1038/sj.onc.1208412.CrossRefPubMed
21.
go back to reference Woodings JA, Sharp SJ, Machesky LM: MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta. Biochem J. 2003, 371: 463-471. 10.1042/BJ20021962.CrossRefPubMedPubMedCentral Woodings JA, Sharp SJ, Machesky LM: MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta. Biochem J. 2003, 371: 463-471. 10.1042/BJ20021962.CrossRefPubMedPubMedCentral
22.
go back to reference Pollard TD, Borisy GG: Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003, 112: 453-465. 10.1016/S0092-8674(03)00120-X.CrossRefPubMed Pollard TD, Borisy GG: Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003, 112: 453-465. 10.1016/S0092-8674(03)00120-X.CrossRefPubMed
23.
go back to reference Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature. 2008, 455: 58-63. 10.1038/nature07228.CrossRefPubMed Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature. 2008, 455: 58-63. 10.1038/nature07228.CrossRefPubMed
24.
go back to reference Zhang X, Zeng Y: Regulation of mammalian microRNA expression. J Cardiovasc Transl Res. 2010, 3: 197-203. 10.1007/s12265-010-9166-x.CrossRefPubMed Zhang X, Zeng Y: Regulation of mammalian microRNA expression. J Cardiovasc Transl Res. 2010, 3: 197-203. 10.1007/s12265-010-9166-x.CrossRefPubMed
25.
go back to reference Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H, Schlapbach R, Dirnhofer S, Tzankov A, Müller A: Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011, 117: 6227-6236. 10.1182/blood-2010-10-312231.CrossRefPubMedPubMedCentral Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H, Schlapbach R, Dirnhofer S, Tzankov A, Müller A: Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011, 117: 6227-6236. 10.1182/blood-2010-10-312231.CrossRefPubMedPubMedCentral
26.
go back to reference Ofir M, Hacohen D, Ginsberg D: MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res. 2011, 9: 440-447. 10.1158/1541-7786.MCR-10-0344.CrossRefPubMed Ofir M, Hacohen D, Ginsberg D: MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res. 2011, 9: 440-447. 10.1158/1541-7786.MCR-10-0344.CrossRefPubMed
27.
go back to reference Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA: STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011, 71: 3658-3668. 10.1158/0008-5472.CAN-10-3647.CrossRefPubMedPubMedCentral Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA: STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011, 71: 3658-3668. 10.1158/0008-5472.CAN-10-3647.CrossRefPubMedPubMedCentral
Metadata
Title
MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma
Authors
Jian Wang
Jingwu Li
Junling Shen
Chen Wang
Lili Yang
Xinwei Zhang
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-227

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine